General
Isolation of compounds were done with reverse column chromatography using RP-18 (40–63 μm, Merck, Germany), and recycling preparative HPLC equipped with UV and RI detectors (LC-908, Hitachi, Japan) using a YMC-M-18 column (250 × 20 mm i.d., YMC, Japan). The structures of compounds were elucidated using spectral methods 1H NMR, APT, COSY, HMBC, FT-IR, UV–vis and HR-ESIMS. The NMR spectra were acquired with Bruker Avance. The Infra red spectra were obtained by JASCO 302-A spectrophotometer, with KBr discs. The HRESI-MS spectra were acquired with Waters Q-TOF Micro YA019 mass spectrometer in m/z and EI-MS spectra with Varian MAT 112 or MAT 312 spectrometers.
Plant material
Aerial flowering parts of Euphorbia microsciadia (Euphorbiaceae) was collected from Ghalil-e-Shirvan, Northern Khorasan province (Iran). Plant material was identified by Y. Naseh, plant taxonomist and a voucher specimen (nos. 2023) deposited in the herbarium of the Faculty of Pharmacy, and Pharmaceutical Sciences at the Isfahan University of Medical Sciences (Iran).
Extraction and isolation
The air-dried powder of the plant material (4.5 kg) was soaked in methanol (20 L × 3) at room temperature for two weeks, and the resulting extract was concentrated to a green gummy residue. Methanolic extract was dissolved in distilled water and defatted with pet. ether. The defatted aqueous extract was further fractionated with EtOAc and BuOH. The butanolic fractions were subjected on MPLC (RP18; H2O/ MeCN, 5→50) to afford four fractions: F1–4. TLC Scanner analysis showed that F3 contained flavonoids. Therefore, F3 eluted with H2O/MeCN (7:3), was chromatographed on RP-18 CC (H2O/ MeCN, 7:3) to render several fractions: F3a-h. Then, F3b, contained mixtures of flavonoids and pigments, was further separated on another RP-18 CC (H2O/MeCN, 7:3) to yield F3b1-F3b7. Then, F3b4, and F3b5 each about 50 mg was purified by polyamide SC6 (DCM/MeOH, 8→20). Fractions were purified more by recycling HPLC using columns M-18 (MeOH/H2O, 4:6). Finally compounds 1 (11mg), 2 (20 mg), 3 (8 mg), and 4 (20 mg) were obtained as pure compound.
Quercetin 3-O-β-D-glucopyranoside (compound 1)
Pale yellow powder. 1H-NMR (500 MHz, MeOD) δ 3. 22 (ddd, J = 9, 5. 6, 2. 5 Hz, H-5″), 3. 34 (d, J = 9 Hz, H-4››), 3. 41 (t, J = 9 Hz, H-3″), 3. 47 (dd, J = 9, 7. 5 Hz, H-2″), 3. 56 (dd, J = 12, 5. 6 Hz, H-6a″), 3. 70 (dd, J = 12, 2. 5 Hz, H-6b″), 5. 15 (d, J = 7. 5 Hz, H-1″), 6. 11 (d, J = 2. 0 Hz, H-6), 6. 28 (d, J = 2. 0 Hz, H-8), 6. 84 (d, J = 8. 5 Hz, H-5′), 7. 57 (dd, J = 8. 5, 2 Hz, H-6′), 7. 70 (d, J = 2 Hz, H-2′). 13C-NMR (125 MHz, MeOD) δ 62. 5 (C-6″), 71. 2 (C-4″), 75. 7 (C-2″), 78. 1 (C-3″), 78. 3 (C-5″), 94. 8 (C-8), 100. 0 (C-6), 105. 3 (C-1″), 105. 6 (C-10), 117. 7 (C-2′), 116. 1 (C-5′), 122. 9 (C-1′), 123. 1 (C-6′), 135. 7 (C-3), 145.8 (C-3′), 150. 6 (C-4′), 158. 8 (C-2), 158. 4 (C-9), 163. 1 (C-5), 166. 3 (C-7), 179. 5 (C-4). Positive HR-FABMS m/z 465.1070 (calcd. for C21H20O12 + H+, 465. 1027); EI-MS m/z 358, 326, 302, 273, 245, 229, 173, 153, 150, 144, 137, 133, 122, 105, 85, 77, 69, 60.
quercetin 3-O-α-L-rhamnopyranosyl (1→6)- β -D-glucopyranoside (compound 2)
Pale Yellow powder; 1H NMR (500 MHz, DMSO) δ 1. 0 (3H, d, J = 6 Hz, H-6′′′), 3. 06 (m, H-3′′′), 3. 07 (m, H-4′′′), 3. 22 (m, H-3″), 3. 22 (m, H-2′′), 3. 25 (m, H-5′′), 3. 27 (m, H-4′′), 3. 28 (m, H-5′′′), 3. 29 (m, H-6′′′), 3. 39 (m, H-2′′′), 3. 71 (d, J = 10. 5, H-6″), 4. 39 (d, J = 1Hz, H-1″′), 5. 35 (d, J = 7. 5 Hz, H-1″), 6. 19 (d, J = 2 Hz, H-6), 6. 39 (d, J = 2 Hz, H-8), 6. 84 (d, J = 8 Hz, H-5′), 7. 54 (br s, H-2′), 7. 55 (dd, J = 8, 2. 5 Hz, H-6′); 13C NMR (125 MHz, DMSO) δ 17. 8 (C-6″′), 66. 9 (C-6″), 68. 2 (C-5″′), 69. 9 (C-3″′), 70. 3 (C-2″′), 70. 4 (C-4″), 71. 7 (C-4″′), 73. 9 (C-2″), 75. 8 (C-5″), 76. 3 (C-3″), 100. 6 (C-1″′), 101. 1 (C-1″), 93. 4 (C-8), 98. 5 (C-6), 103. 7 (C-10), 115. 0 (C-2′), 116. 0 (C-5′), 120. 9 (C-1′), 121. 3 (C-6′), 129. 9 (C-3), 144. 4 (C-3′), 148. 1 (C-4′), 156. 1 (C-2), 160. 9 (C-5), 163. 8 (C-7) , 177. 0 (C-4). Positive HR-FAB m/z 611.1648 (calcd. for C27H30O16 +H+, 611. 1606, Δ 6. 9 ppm). ESI-MS m/z 611 (M), 465 (M-Rha), 303 (M-Rha-Glc); EI-MS: 302, 273, 245, 228, 200, 153, 150, 137, 109, 108, 91, 81, 71, 69, 66.
Myricetin 3-O-β-D-galactopyranoside (compound 3)
Pale yellow powder. 1H-NMR (400 MHz, DMSO) δ 3. 26 (m, H-6″), 3. 29 (m, H-5″ ), 3. 37 (dd, J = 3, 9. 2 Hz, H-3″ ), 3. 47 (dd, J = 14, 9. 6 Hz, H-6b″ ), 3. 61 (dd, J = 7. 6, 9. 2 Hz, H-2″), 3. 65 (d, J = 3 Hz, H-4″), 5. 29 (d, J = 7. 6 Hz, H-1″), 6. 18 (d, J = 1. 6 Hz, H-6), 6. 37 (2H, d, J = 1. 6 Hz, H-8), 7. 19 (2H, s, H-2′, H-6′), 8. 00 (OH), 12. 58 (5-OH). 13C-NMR (125 MHz, DMSO) δ 60. 1 (C-6″), 67. 9 (C-4″), 71. 2 (C-2″), 73. 2 (C-3″), 75. 9 (C-5″), 93. 3 (C-8), 98. 6 (C-6), 102. 0 (C-1″), 105. 8 (C-10), 108. 6 (C-2″, C-6″), 120. 0 (C-1′), 133. 7 (C-3), 136. 8 (C-4′), 145. 2 (C-3′, C-5′), 156. 2 (C-2, C-9), 161. 2 (C-5), 164. 3 (C-7), 177. 6 (C-4). Positive HR-FABMS m/z 481.0996 (calcd. for C21H20O13 + H+, 481. 0976); EI-MS m/z 302, 286, 231, 201, 164, 153, 149,126, 105, 95, 84, 73, 66.
Quercetin 3-O-β-D-galactopyranoside (compound 4)
Pale yellow powder. 1H-NMR (500 MHz, MeOD) δ 3. 46 (dd, J = 6. 5, 6 Hz, H-5′′), 3. 53 (m, H-3′′), 3. 56 (m, H-6a′′), 3. 63 (dd, J = 11. 5, 6 Hz, H-6b′′), 3. 81 (dd, J = 9. 5, 7. 5 Hz, H-2′′), 3. 84 (br-d, J = 3 Hz, H-4′′), 5. 12 (d, J = 7. 5 Hz, H-1′′), 6. 16 (d, J = 2. 5 Hz, H-6), 6. 35 (d, J = 2. 0 Hz, H-8), 6. 85 (d, J = 8. 5 Hz, H-5′), 7. 57 (dd, J = 8. 5, 2 Hz, H-6′), 7. 82 (d, J = 2 Hz, H-2′). 13C-NMR (150 MHz, MeOD) δ 61. 9 (C-6′′), 69. 8 (C-4′′), 73. 4 (C-2′′), 75. 0 (C-3′′), 77. 2 (C-5′′), 95. 2 (C-8), 100. 5 (C-6), 105. 2 (C-1′′), 105. 5 (C-10), 117. 3 (C-2′), 116. 0 (C-5′), 122. 8 (C-1′), 123. 1 (C-6′), 135. 6 (C-3), 145. 9 (C-3′), 150. 8 (C-4′), 158. 4 (C-2), 158. 4 (C-9), 163. 0 (C-5), 169. 0 (C-7), 179. 5 (C-4). Positive HR-FABMS m/z 465.1085 (calcd. for C21H20O12 + H+, 465. 1027); EI-MS m/z 302, 273, 245, 229, 173, 153, 150, 144, 137, 133, 85, 60.
Lymphocyte proliferation assay
Peripheral human blood lymphocytes were incubated with different concentrations of the test compounds (0. 5, 5, and 50 μg/mL) in triplicates in supplemented RPMI-1640 along with phytohemagglutinin (PHA) at 37º C in CO
2 environment for 72 h. Further incubation for 18 hours after the addition of thymidine (
3H) (Amersham, Buckinghamshire, UK) was done and cells were harvested using cell harvester (Inotech Dottikon, Switzerland). Finally, proliferation level was determined by the radioactivity count as CPM reading recorded from
β-scintillation counter (Beckman Coulter, LS 6500, Fullerton, CA, USA) (
7).
Statistical analysis
All data are reported as mean ± SD of the mean and the IC50 values were calculated using Excel based program. One-way ANOVA: post-hoc dunnett test was also used and * p < 0.05; ** p < 0.01; *** p < 0.001 were considered to indicate a statistically significant difference.